KORU Medical Systems R&D Spending Growth & History (KRMD)
KORU Medical Systems's r&d spending was $4.4M for fiscal 2025.
View full KORU Medical Systems company overviewKORU Medical Systems annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.4M | −$870,728 | −16.56% |
| 2024 | 2024-12-31 | $5.3M | −$484,312 | −8.43% |
| 2023 | 2023-12-31 | $5.7M | $786,039 | +15.86% |
| 2022 | 2022-12-31 | $5.0M | $2.5M | +100.36% |
| 2021 | 2021-12-31 | $2.5M | $1.2M | +90.76% |
| 2020 | 2020-12-31 | $1.3M | $556,279 | +75.12% |
| 2019 | 2019-12-31 | $740,475 | $499,351 | +207.09% |
| 2018 | 2018-12-31 | $241,124 | $190,537 | +376.65% |
| 2017 | 2017-12-31 | $50,587 | — | — |
| 2016 | 2017-02-28 | $237,486 | $30,204 | +14.57% |
| 2015 | 2016-02-29 | $207,282 | −$260,872 | −55.72% |
| 2014 | 2015-02-28 | $468,154 | $250,004 | +114.60% |
| 2013 | 2014-02-28 | $218,150 | $70,574 | +47.82% |
| 2012 | 2013-02-28 | $147,576 | $57,247 | +63.38% |
| 2011 | 2012-02-29 | $90,329 | $54,810 | +154.31% |
| 2010 | 2011-02-28 | $35,519 | — | — |
KORU Medical Systems quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | −$125,589 | −10.51% |
| Q1 2026 | 2026-03-31 | $1.3M | $201,994 | +18.12% |
| Q4 2025 | 2025-12-31 | $1.1M | $30,518 | +2.74% |
| Q3 2025 | 2025-09-30 | $933,107 | −$600,738 | −39.17% |
| Q2 2025 | 2025-06-30 | $1.2M | $60,557 | +5.34% |
| Q1 2025 | 2025-03-31 | $1.1M | −$361,065 | −24.47% |
| Q4 2024 | 2024-12-31 | $1.1M | −$173,324 | −13.46% |
| Q3 2024 | 2024-09-30 | $1.5M | $240,589 | +18.60% |
| Q2 2024 | 2024-06-30 | $1.1M | −$462,382 | −28.96% |
| Q1 2024 | 2024-03-31 | $1.5M | −$89,195 | −5.70% |
| Q4 2023 | 2023-12-31 | $1.3M | −$354,466 | −21.59% |
| Q3 2023 | 2023-09-30 | $1.3M | $431,108 | +50.00% |
| Q2 2023 | 2023-06-30 | $1.6M | $292,883 | +22.46% |
| Q1 2023 | 2023-03-31 | $1.6M | $416,514 | +36.27% |
| Q4 2022 | 2022-12-31 | $1.6M | $692,051 | +72.85% |
| Q3 2022 | 2022-09-30 | $862,148 | $62,128 | +7.77% |
| Q2 2022 | 2022-06-30 | $1.3M | $916,853 | +236.99% |
| Q1 2022 | 2022-03-31 | $1.1M | $811,514 | +240.92% |
| Q4 2021 | 2021-12-31 | $949,930 | $597,813 | +169.78% |
| Q3 2021 | 2021-09-30 | $800,020 | $409,604 | +104.91% |
| Q2 2021 | 2021-06-30 | $386,878 | $88,682 | +29.74% |
| Q1 2021 | 2021-03-31 | $336,841 | $80,816 | +31.57% |
| Q4 2020 | 2020-12-31 | $352,117 | $62,096 | +21.41% |
| Q3 2020 | 2020-09-30 | $390,416 | $220,156 | +129.31% |
| Q2 2020 | 2020-06-30 | $298,196 | $119,961 | +67.30% |
| Q1 2020 | 2020-03-31 | $256,025 | $154,066 | +151.11% |
| Q4 2019 | 2019-12-31 | $290,021 | $209,631 | +260.77% |
| Q3 2019 | 2019-09-30 | $170,260 | $43,337 | +34.14% |
| Q2 2019 | 2019-06-30 | $178,235 | $154,272 | +643.79% |
| Q1 2019 | 2019-03-31 | $101,959 | $92,111 | +935.33% |
| Q4 2018 | 2018-12-31 | $80,390 | — | — |
| Q3 2018 | 2018-09-30 | $126,923 | $112,071 | +754.59% |
| Q2 2018 | 2018-06-30 | $23,963 | −$877 | −3.53% |
| Q1 2018 | 2018-03-31 | $9,848 | −$36,058 | −78.55% |
| Q2 2017 | 2017-09-30 | $14,852 | −$60,346 | −80.25% |
| Q1 2017 · Jun 30 | 2017-06-30 | $24,840 | −$32,563 | −56.73% |
| Q1 2017 · Mar 31 | 2017-03-31 | $45,906 | — | — |
| Q3 2016 | 2016-11-30 | $59,142 | $7,578 | +14.70% |
| Q2 2016 · Sep 30 | 2016-09-30 | $75,198 | — | — |
| Q2 2016 · Aug 31 | 2016-08-31 | $67,686 | $28,975 | +74.85% |
| Q1 2016 · Jun 30 | 2016-06-30 | $57,403 | — | — |
| Q1 2016 · May 31 | 2016-05-31 | $56,668 | $3,003 | +5.60% |
| Q4 2015 | 2016-02-29 | $63,342 | $1,893 | +3.08% |
| Q3 2015 | 2015-11-30 | $51,564 | −$65,321 | −55.88% |
| Q2 2015 | 2015-08-31 | $38,711 | −$119,713 | −75.56% |
| Q1 2015 | 2015-05-31 | $53,665 | −$77,731 | −59.16% |
| Q4 2014 | 2015-02-28 | $61,449 | −$24,967 | −28.89% |
| Q3 2014 | 2014-11-30 | $116,885 | $66,021 | +129.80% |
| Q2 2014 | 2014-08-31 | $158,424 | $115,308 | +267.44% |
| Q1 2014 | 2014-05-31 | $131,396 | $93,642 | +248.03% |
| Q4 2013 | 2014-02-28 | $86,416 | $50,292 | +139.22% |
| Q3 2013 | 2013-11-30 | $50,864 | $14,802 | +41.05% |
| Q2 2013 | 2013-08-31 | $43,116 | $6,101 | +16.48% |
| Q1 2013 | 2013-05-31 | $37,754 | −$621 | −1.62% |
| Q4 2012 | 2013-02-28 | $36,124 | −$4,903 | −11.95% |
| Q3 2012 | 2012-11-30 | $36,062 | $9,456 | +35.54% |
| Q2 2012 | 2012-08-31 | $37,015 | $27,046 | +271.30% |
| Q1 2012 | 2012-05-31 | $38,375 | $25,648 | +201.52% |
| Q4 2011 | 2012-02-29 | $41,027 | — | — |
| Q3 2011 | 2011-11-30 | $26,606 | $18,162 | +215.09% |
| Q2 2011 | 2011-08-31 | $9,969 | −$425 | −4.09% |
| Q1 2011 | 2011-05-31 | $12,727 | — | — |
| Q3 2010 | 2010-11-30 | $8,444 | — | — |
| Q2 2010 | 2010-08-31 | $10,394 | — | — |
KORU Medical Systems r&d spending trends
Over the last five fiscal years, KORU Medical Systems's r&d spending increased from $1.3M to $4.4M, a change of $3.1M. The latest reported quarter, Q2 2026, shows $1.1M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review KORU Medical Systems source filings ↗